Psychiatry and Neurology, Neurology · Webster, TX
NPI
1124391198
Since 2012
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
6
Hospital affiliations
905 W Medical Center Blvd Ste 301
Webster, TX, 77598
Phone (281) 724-8334
Groups this clinician bills Medicare through
Medicare paid, 2024
$391K
27,471 services
Medicare patients, 2024
383
Average age 73
Drug cost, 2024
$14.9M
3,905 prescriptions
Company payments, 2025
$3,612
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohamed A Khalil was code A9575 (injection, gadoterate meglumine, 0.1 ml), 18,780 times for 96 patients. In total Mohamed A Khalil billed 27,471 services in 77 codes, and Medicare paid $391K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| A9575 Injection, gadoterate meglumine, 0.1 ml | Office | 18,780 | 96 | $0.10 | $1,788 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,819 | 110 | $0.09 | $159 |
| 96367 Intravenous Infusion, Hydration | Office | 740 | 17 | $21.33 | $16K |
| 96366 Intravenous Infusion, Hydration | Office | 590 | 17 | $15.21 | $8,976 |
| 95886 Electrical Nerve Conductivity | Office | 467 | 140 | $72.04 | $34K |
| 99213 Office E&M - Established | Office | 359 | 137 | $68.04 | $24K |
| 96365 Intravenous Infusion, Hydration | Office | 313 | 19 | $46.58 | $15K |
| 99214 Office E&M - Established | Office | 305 | 206 | $94.87 | $29K |
| 76942 Ultrasound - Nonspecific | Office | 253 | 84 | $44.41 | $11K |
| 64640 Musculoskeletal | Office | 250 | 81 | $273.33 | $68K |
| J3490 Unclassified drugs | Office | 236 | 13 | $0.57 | $133 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 218 | 13 | $0.61 | $134 |
| 95819 Neurologic | Office | 157 | 150 | $337.75 | $53K |
| 99205 Office E&M - New | Office | 146 | 146 | $158.38 | $23K |
| 36415 Venipuncture Blood Collection | Office | 131 | 100 | $8.65 | $1,133 |
By year: 2022 $545K for 12,953 services; 2023 $419K for 12,305 services; 2024 $391K for 27,471 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 131 | 100 | $8.65 | $1,133 |
| 82565 Clinical Chemistry | 68 | 60 | $5.02 | $341 |
Medicare prescription drug claims, 2024
In 2024, the drug Mohamed A Khalil prescribed most often to Medicare patients was Memantine Hcl, with 540 prescriptions and refills. In total Mohamed A Khalil wrote 3,905 Medicare prescriptions that cost $14.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Memantine Hcl Generic | 540 | 825 | 173 | $11K |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 365 | 365 | 30 | $5.7M |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 361 | 367 | 26 | $2.8M |
| Donepezil Hcl Generic | 249 | 450 | 86 | $2,558 |
| Gabapentin Generic | 176 | 210 | 57 | $1,840 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 119 | 119 | Under 11 | $1.8M |
| Sodium Chloride 0.9 % Sodium Chloride | 117 | 117 | 11 | $787 |
| Memantine Hcl Er Memantine Hcl | 99 | 131 | 36 | $6,151 |
| Pregabalin Generic | 86 | 115 | 20 | $1,855 |
| Clonazepam Generic | 75 | 82 | 17 | $242 |
| Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) | 71 | 116 | 28 | $1,571 |
| Botox Onabotulinumtoxina | 69 | 207 | 44 | $127K |
| Gammaked Immune Globul G/Gly/Iga Avg 46 | 68 | 68 | Under 11 | $1.6M |
| Amantadine Amantadine Hcl | 67 | 91 | 24 | $2,255 |
| Levetiracetam Generic | 63 | 101 | 20 | $1,913 |
Brand drugs: 1,420 claims; generic drugs: 2,465 claims; opioid claims: 38.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohamed A Khalil $3,612 ($3,612 in general payments such as food, travel and fees) from 29 companies. The largest payer was UCB, Inc. with $536.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 19 | $536 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $401 |
| Abbvie Inc. ABBV | 18 | $330 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 10 | $247 |
| ANI Pharmaceuticals, Inc. ANIP | 10 | $190 |
| Neurocrine BioSciences, Inc. NBIX | 8 | $168 |
| TG Therapeutics, Inc. TGTX | 9 | $167 |
| Grifols USA, LLC | 8 | $159 |
| Argenx US, Inc. ARGX | 5 | $152 |
| Eisai Inc. 4523.T | 7 | $150 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.